GSK celebrates 100 years in India with former MDs, highlighting resilience and reinvention in the pharmaceutical industry.

While generics may dominate due to cost advantages and meeting needs of a developing economy, there is a growing thrust ...

We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...

Revenue from operations rose to Rs 1,010 crore for the September quarter compared with Rs 957 crore in the year-ago period, ...

New Delhi: GlaxoSmithKline's antibiotic drug Augmentin has risen to the top slot in the Indian pharmaceutical market, pushing the popular anti-diabetes drug Glycomet GP to the second slot.

GSK is to spend over US $1 billion to increase its stakes in its consumer healthcare subsidiaries in India and Nigeria. GSK will increase its share of its publicly-listed Consumer Healthcare ...

India's GlaxoSmithKline Pharmaceuticals reported a higher second-quarter adjusted profit on Tuesday, driven by strong demand for its generic drugs and vaccines.

Under his leadership, the North office was responsible for numerous global and Indian brands like, PepsiCo, Nestle, GSK, Hero ...

India's Intellectual Property Appellate Board (IPAB) has revoked the patent for global pharmaceutical company, GlaxoSmithKline's anti-cancer drug Tykerb. Tykerb (lapatinib) is a dual tyrosine ...

GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs ...

Prior to JWT/WT, North, Chauhan was the head of the agency's Sri Lanka operations and JWT (South). Chauhan has also worked at ...

GlaxoSmithKline Pharma, celebrating 100 years in India, is shifting to a specialty-focused model by entering the oncology market and expanding its preventive healthcare through adult vaccines.